1. A Journal Club on Lipid Management:

2. Program Goals

3. JUPITER Increased Incidence of T2D With Rosuvastatin

4. Statins and New-Onset T2D Meta-Analysis of 13 Clinical Trials

5. T2D Risk: No Difference Between Statins

6. T2D Risk Increases With Statin Potency Meta-Analysis of 5 Clinical Trials

7. Certain Statins Increase the Risk for New-Onset T2D

8. Pitavastatin Does Not Adversely Affect FBG, HbA1c, or T2D Development

9. Pitavastatin Has Neutral Effect on FBG Across the Dose Range

10. J-PREDICT Study Design

11. J-PREDICT Primary Outcome: Cumulative Incidence of Diabetes

12. TNT: Risk for New-Onset T2D Stratified by Risk Factors and Statin Dose

13. Risk for New-Onset T2D Stratified by Age

14. Multidisciplinary Team Approach to Reduce Risk for Diabetes

15. JUPITER: CV Benefit vs T2D Risk

16. Statin-Associated T2D Implications for Clinical Care

17. How Statins Could Impair Glucose and Insulin Metabolism

18. Statin Selection Consideration

19. Abbreviations

20. Abbreviations (cont)